Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0
Stock impact report

Roche's Alecensa latest beneficiary of faster China drug approvals [Reuters]

ROCHE HOLDING LTD S/ADR (RHHBY) 
NASDAQ:AMEX Investor Relations: roche.com/investors.htm
Company Research Source: Reuters
Roche's Alecensa latest beneficiary of faster China drug approvals | Reuters Reuters Staff 1 Min Read ZURICH (Reuters) - Chinese regulators are speeding up drug approvals, with Roche’s Alecensa cancer medicine the latest beneficiary in a market that is growing increasingly important for international pharmaceuticals companies’ growth plans. China’s National Drug Administration backed the Swiss drugmaker’s Alecensa to treat a kind of lung cancer, called anaplastic lymphoma kinase-, or ALK-positive, less than a year after European and U.S. approvals. Reporting by John Miller All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. © 2018 Reuters. All Rights Reserved. Roche's Alecensa latest beneficiary of faster China drug approvals ZURICH (Reuters) - Chinese regulators are speeding up drug approvals, with Roche’s Alecensa cancer medicine the latest beneficiary in a market that is growing increasingly important for international pharmace Show less Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for RHHBY alerts
Opt-in for
RHHBY alerts

from News Quantified
Opt-in for
RHHBY alerts

from News Quantified